ArticleThe Medical journal of Australia2025
The epidemiology of acute rheumatic fever and rheumatic heart disease in Queensland, 2017-2021: a population-level cohort study using linked administrative data.
Article in The Medical journal of Australia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo determine the incidence and prevalence of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) in Queensland during the period 2017-2021. STUDY
designPopulation-level retrospective cohort study using linked administrative data. SETTING,
participantsQueensland residents aged younger than 45 years for ARF and younger than 55 years for RHD, identified from hospital, emergency department, death and Queensland RHD Register records for the period 1 January 2017 to 31 December 2021.
main outcome measuresAge-specific and age-standardised incidence and prevalence of ARF and RHD; and age-standardised incidence and prevalence ratios comparing Indigenous and non-Indigenous populations.
results736 ARF episodes occurred among 670 people (395 [54%] female participants; 609 [83%] Indigenous). Of 4519 prevalent RHD cases aged < 55 years who were alive on 1 July 2021, 2655 (59%) were female, 2169 (48%) were Indigenous, and 1846 (41%) had severe disease. Previous ARF was recorded for 362 cases (8%). Among RHD cases aged younger than 25 years, 633 of 790 Indigenous individuals (80%) and 133 of 408 non-Indigenous individuals (33%) had RHD Register records. Indigenous age-standardised incidence (< 45 years) was 60.2 times higher (95% CI, 55.6-64.2) than non-Indigenous incidence for first ever ARF, 68.6 times higher (95% CI, 62.3-72.5) for total ARF, and 18.9 times higher (95% CI, 13.5-24.1) for RHD. For Indigenous people aged < 55 years, prevalence was 22.6 times higher (95% CI, 16.2-27.3) for ARF/RHD, 18.4 times higher (95% CI, 12.9-24.1) for RHD, and 12.1 times higher (95% CI, 8.3-15.9) for severe RHD. The overall burden of ARF and RHD was highest in northern Queensland health districts, whereas cases in the non-Indigenous population were concentrated in metropolitan south-east Queensland.
conclusionsThe vast disparity in ARF and RHD burden between Indigenous and non-Indigenous Queenslanders indicates an urgent need for targeted, community-led prevention strategies. Under-representation of non-Indigenous youth in the RHD Register suggests improved clinical awareness and reporting is needed. Further investigation is warranted to inform equitable responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.